Dual inhibition: Combining epidermal growth factor-targeted therapies in non-small-cell lung cancer

Cheryl Ho, Angela Davies, Philip Mack, David R Gandara

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The epidermal growth factor receptor (EGFR) pathway is an important target in the treatment of advanced non-small-cell lung cancer. Therapeutic modulation of this pathway has focused on inhibiting the EGFR tyrosine kinase or competitively binding the receptor. Each method of EGFR inhibition is imperfect, with alternate cellular mechanisms variably enabling continued proliferation and malignant growth. In addition, de novo or acquired resistance is common with either one of these approaches. The use of both strategies simultaneously to block the EGFR signaling cascade, so-called dual inhibition, might theoretically overcome these limitations and improve efficacy. Preclinical data support this concept, and clinical trials are under way to investigate the safety and efficacy of combined EGFR inhibition.

Original languageEnglish (US)
Pages (from-to)420-424
Number of pages5
JournalClinical Lung Cancer
Volume8
Issue number7
DOIs
StatePublished - Jul 2007

Fingerprint

Epidermal Growth Factor Receptor
Epidermal Growth Factor
Non-Small Cell Lung Carcinoma
Therapeutics
Protein-Tyrosine Kinases
Clinical Trials
Safety
Growth

Keywords

  • Monoclonal antibodies
  • Stable disease
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Cite this

Dual inhibition : Combining epidermal growth factor-targeted therapies in non-small-cell lung cancer. / Ho, Cheryl; Davies, Angela; Mack, Philip; Gandara, David R.

In: Clinical Lung Cancer, Vol. 8, No. 7, 07.2007, p. 420-424.

Research output: Contribution to journalArticle

@article{96153ffc3da04ef890034ed711d0e97c,
title = "Dual inhibition: Combining epidermal growth factor-targeted therapies in non-small-cell lung cancer",
abstract = "The epidermal growth factor receptor (EGFR) pathway is an important target in the treatment of advanced non-small-cell lung cancer. Therapeutic modulation of this pathway has focused on inhibiting the EGFR tyrosine kinase or competitively binding the receptor. Each method of EGFR inhibition is imperfect, with alternate cellular mechanisms variably enabling continued proliferation and malignant growth. In addition, de novo or acquired resistance is common with either one of these approaches. The use of both strategies simultaneously to block the EGFR signaling cascade, so-called dual inhibition, might theoretically overcome these limitations and improve efficacy. Preclinical data support this concept, and clinical trials are under way to investigate the safety and efficacy of combined EGFR inhibition.",
keywords = "Monoclonal antibodies, Stable disease, Tyrosine kinase inhibitors",
author = "Cheryl Ho and Angela Davies and Philip Mack and Gandara, {David R}",
year = "2007",
month = "7",
doi = "10.3816/CLC.2007.n.025",
language = "English (US)",
volume = "8",
pages = "420--424",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "7",

}

TY - JOUR

T1 - Dual inhibition

T2 - Combining epidermal growth factor-targeted therapies in non-small-cell lung cancer

AU - Ho, Cheryl

AU - Davies, Angela

AU - Mack, Philip

AU - Gandara, David R

PY - 2007/7

Y1 - 2007/7

N2 - The epidermal growth factor receptor (EGFR) pathway is an important target in the treatment of advanced non-small-cell lung cancer. Therapeutic modulation of this pathway has focused on inhibiting the EGFR tyrosine kinase or competitively binding the receptor. Each method of EGFR inhibition is imperfect, with alternate cellular mechanisms variably enabling continued proliferation and malignant growth. In addition, de novo or acquired resistance is common with either one of these approaches. The use of both strategies simultaneously to block the EGFR signaling cascade, so-called dual inhibition, might theoretically overcome these limitations and improve efficacy. Preclinical data support this concept, and clinical trials are under way to investigate the safety and efficacy of combined EGFR inhibition.

AB - The epidermal growth factor receptor (EGFR) pathway is an important target in the treatment of advanced non-small-cell lung cancer. Therapeutic modulation of this pathway has focused on inhibiting the EGFR tyrosine kinase or competitively binding the receptor. Each method of EGFR inhibition is imperfect, with alternate cellular mechanisms variably enabling continued proliferation and malignant growth. In addition, de novo or acquired resistance is common with either one of these approaches. The use of both strategies simultaneously to block the EGFR signaling cascade, so-called dual inhibition, might theoretically overcome these limitations and improve efficacy. Preclinical data support this concept, and clinical trials are under way to investigate the safety and efficacy of combined EGFR inhibition.

KW - Monoclonal antibodies

KW - Stable disease

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=34547818723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547818723&partnerID=8YFLogxK

U2 - 10.3816/CLC.2007.n.025

DO - 10.3816/CLC.2007.n.025

M3 - Article

C2 - 17681094

AN - SCOPUS:34547818723

VL - 8

SP - 420

EP - 424

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 7

ER -